A synthetic peptide (CKS-17) homologous to a highly conserved region of the retroviral transmembrane protein pl5E was tested for its effect on receptor expression on monocytes. The CKS-17 amino acid sequence is present in several retroviruses including human T-cell lymphotropic virus types I and II and human immunodeficiency virus. The CKS-17 peptide has been previously shown to inhibit monocyte superoxide production, natural killer cell activity, polyclonal B-cell activation, and monocyte-mediated killing by inactivation of interleukin-1. In this study, we demonstrated that the anti-CD4 monoclonal antibody OKT4 binds strongly in vitro to CKS-17-treated human blood monocytes, whereas other antibodies tested were not reactive. This observed binding was the result of direct interaction of OKT4 antibody with the CKS-17 peptide. Moreover, a partial homology was found in amino acid sequence analysis of the CD4 epitope and the CKS-17 peptide.
Several in vivo and in vitro studies have shown that retroviruses can produce immunosuppression in different animal hosts. Different components of the virus are believed to be responsible for these immunosuppressive effects. The retroviral transmembrane envelope protein piSE, a 26-amino-acid peptide, inhibits several immune functions of macrophages and lymphocytes (7) . This transmembrane sequence is conserved among several murine, feline, simian, and human retroviruses including human T-cell lymphotropic virus types I and II and human immunodeficiency virus (HIV) (12) .
CKS-17 peptide is a synthetic 17-amino-acid peptide sequence which represents the first 16 amino acids of the piSE envelope protein. This peptide has several major effects on cells of the immune system. Its effects on monocytes and lymphocytes include the inhibition of mitogen-and alloantigen-stimulated proliferation of human lymphocytes (2) , proliferation of a cloned murine cytotoxic T-cell line (2) , immunoglobulin synthesis in B cells (9) , the respiratory burst of human monocytes (5) , and the inhibition of human natural killer cell-mediated cytotoxicity (6) . Recently, inhibition of gamma interferon production by human peripheral mononuclear cells (MNC) has been demonstrated (11) . We investigated the effect of CKS-17 coupled to human serum albumin (HSA) on the modulation of CD4 membrane receptor expression on monocytes.
MATERIALS AND METHODS CKS-17 peptides. CKS-17 and HSA-coupled CKS-17 peptides were the generous gift from George J. Cianciolo and Ralph Snyderman, Genentech Inc., South San Francisco, Calif. The methods for peptide synthesis and its coupling to carrier protein have been described previously (5) . Briefly, CKS-17 (LQNRRGLDLLFLKEGGL) was prepared by Merrifield solid-phase synthesis techniques and purified by using ion-exchange and reverse-phase high-pressure liquid chromatography, and its sequence was verified by highpressure liquid chromatography and amino acid analysis (5). CKS-17 was coupled to the carrier protein HSA by the following method. Peptide (1.0 mM) and HSA (0.030 mM) were mixed in 0.1 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride for 10 h at 22°C at pH 5.0. An equal volume of 1.0 M glycine was then added, and the mixture was rotated overnight at 4°C and then extensively dialyzed against Hanks balanced salt solution. Efficiency of coupling was estimated to be 30% by using radiolabeled peptide, resulting in conjugated material with a final peptide concentration of 0.15 mM lated microbeads (2.39 ,um in diameter) (Seragen Diagnostics, Indianapolis, Ind.) were coated with different peptides by the method of Nathan and Cohn (10) with minor modifications. The carboxylated microbeads were washed three times with carbonate buffer (pH 9.6) and then three times with phosphate buffer (pH 4.5). Microbeads were then incubated with 2% 1-cyclohexyl-3(2-morpholinoethyl)-carbodiimide metho-p-toluene sulfonate for 3 h at room temperature and then washed with borate buffer (pH 8.5) and subsequently incubated overnight on a rotary shaker with the peptide to be bound at room temperature. The next day, the microbeads were treated with 1 M glycine for 60 min to block unbound ligand, washed, and kept in phosphate buffer (pH 7.4) with 5% glycerol at 4°C until used.
Effects of CKS-17 on monoclonal antibodies binding to monocytes or coated microbeads. MNC were incubated with 15 ,uM CKS-17-HSA per ml for 20 min at 37 or 4°C. Following treatment, cells were washed once with Hanks balanced salt solution and stained with different types of monoclonal antibodies. Surface receptor expression was studied with the following murine monoclonal antibodies: anti-LeuM3 (Becton Dickinson and Co., Mountain View, Calif.), Mac-1 (gift from Donald Anderson, Baylor University, Houston, Tex.), and OKIa, OKT4, and OKT4A (Ortho Diagnostics, Inc., Raritan, N.J.). Fluorescein-or rhodamine-labeled F(ab')2 goat anti-mouse antibodies (Tago Inc., Burlingame, Calif.) were used as second antibodies. MNC surface receptors and monoclonal antibody binding to coated microbeads were assayed as follows. Cells were initially washed with cold phosphate-buffered saline (GIBCO Laboratories, Chagrin Falls, Ohio) supplemented with 0.1% bovine serum albumin (Behring Diagnostics, La Jolla, Calif.) and 0.01% sodium azide (Fisher Scientific Co., Pittsburgh, Pa.); beads were washed with phosphate-buffered saline only. Cells or beads were then incubated with monoclonal antibody for 30 min at 4°C and then washed once and incubated with fluorescein-or rhodamine-labeled goat antimouse antibodies for 30 min at 4°C. Cells or beads were then washed, and fluorescence was determined with an EPICS C flow cytometer (Coulter Immunology, Hialeah, Fla.). The results were expressed as the mean of the logarithm of green or red fluorescence.
RESULTS
Binding of CKS-17-HSA to monocytes. CKS-17-HSA-treated MNC were stained with different types of monoclonal antibodies, and monocytes were identified by forward and right-angle scatter on the flow cytometer. No significant changes were observed in the binding of the monoclonal antibodies OKT4A, OKIa, LeuM3, and Mac-i to the CKS-17-HSA-treated monocytes or to the controls. However, a significant increase in the binding of monoclonal antibody OKT4 was observed for the CKS-17-HSA-treated monocytes (Table 1 Binding of CKS-17-HSA to EBV-transformed B cells and carboxylated microbeads. To determine whether the increase in OKT4 binding to CKS-17-treated cells was due to upregulation of CD4 by CKS-17-HSA or whether monoclonal antibody OKT4 can bind directly to CKS-17-HSA, we studied the OKT4 binding to CKS-17-HSA-treated EBVtransformed B cells and CKS-17-HSA-coated microbeads. Since EBV-transformed B lymphocytes lack the CD4 receptor, OKT4 would not be expected to bind to them. After incubation with CKS-17-HSA for 20 min, however, OKT4 bound significantly to the cells, while no binding was seen with the HSA treatment alone ( Table 2 ). The direct binding of OKT4 to CKS-17-HSA peptide was also tested by using microbeads which were coated with three different peptides, CKS-17-HSA, CKS-17, and HSA; the last two peptides were used as controls. Monoclonal antibody OKT4 bound significantly to CKS-17-HSA-treated microbeads (Fig. 1) , while no binding occurred with the other controls or with the monoclonal antibodies OKT4A, Mac-1, LeuM3, and OKIa (Table 3) .
Amino acid sequence similarity of CD4 glycoprotein and CKS-17 peptide. Using the Bionet resource, we studied a computer-assisted comparison of CKS-17 and CD4 to determine the presence of possible homologies between the two peptides which may explain the binding of anti-CD4 antibody to CKS-17. Analysis of both sequences revealed a partial homology between CKS-17 peptide and amino acids 202 to 218 and 408 to 424 in the CD4 protein (Fig. 2) . The first region is present in the binding epitope of the OKT4 and not of the OKT4A antibody (8) . The sequence homology between the CKS-17 peptide and the HIV envelope protein gp120 is also shown in Fig. 2 . 
DISCUSSION
We have investigated the antibody-binding capacity of a well-conserved region of oncogenic retrovirus transmembrane envelope protein pl5E. pi5E and CKS-17 (a synthetic 17-amino-acid peptide present in pl5E) are known to mediate several in vitro inhibitory effects on different cell types (2, 5, 6, 9, 11) . Moreover, peptide is also present in several human retrovirus envelope proteins, including human T-cell lymphotropic virus types I and Il and HIV (12 (4) . Sera tested from 36% of patients with acquired immunodeficiency syndrome contained antibodies that reacted with class Il molecules; the role and significance of these antibodies are unknown (4) .
In summary, we presented data that suggest mimicry between CD4 receptors on monocytes and CKS-17, a synthetic peptide that corresponds to a conserved region of 
